A Study of JNJ-61393215 in the Treatment of Depression
Status:
Recruiting
Trial end date:
2021-10-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of JNJ-61393215 as adjunctive treatment
compared to adjunctive placebo, as assessed by the change from baseline to week 6 on a
17-item Hamilton Depression Rating Scale (HDRS-17) in participants with major depressive
disorder (MDD) with anxious distress with a score greater than or equal to (>=) 2 on item 26
or 27 of the Inventory of Depressive Symptomatology, Clinician Rating -30 (IDS-C30), who have
a suboptimal response to current treatment with a standard antidepressant.